Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vandel

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Pharmacopsychiatry|December 22, 1999
Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotypeE Haffen, P Vandel, F Broly, et al.
Therapie|January 1, 1997
Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoinP Vandel, B Bonin, G Bertschy, et al.
Pharmacological Research|June 1, 1995
Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patientsS Vandel, G Bertschy, P Baumann, et al.
L'Encephale|May 1, 1996
[Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration]B Bonin, G Bertschy, P Baumann, et al.
European Journal of Clinical Pharmacology|January 1, 1993
Minor and clinically non-significant interaction between toloxatone and amitriptylineS Vandel, G Bertschy, M C Perault, et al.
Neuropsychobiology|January 1, 1992
Tricyclic antidepressant plasma levels after fluoxetine additionS Vandel, G Bertschy, B Bonin, et al.
European Journal of Clinical Pharmacology|January 19, 2000
Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypesP Vandel, E Haffen, S Vandel, et al.
Clinical Neuropharmacology|January 1, 1992
Metabolic interaction between tricyclic antidepressant and fluvoxamine and fluoxetine, a pharmacogenetic approachG Bertschy, S Vandel, T Francois, et al.
Therapie|January 1, 1995
[Undesirable effects of drugs. Epidemiologic study at a psychiatric service of a university hospital]P Vandel, P Bizouard, S Vandel, et al.
European Journal of Clinical Pharmacology|May 11, 2000
Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?E Haffen, P Vandel, G Paintaud, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Pharmacopsychiatry|December 22, 1999
Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotypeE Haffen, P Vandel, F Broly, et al.
Therapie|January 1, 1997
Observations of the interaction between tricyclic antidepressants and fluvoxamine in poor metabolizers of dextromethorphan and mephenytoinP Vandel, B Bonin, G Bertschy, et al.
Pharmacological Research|June 1, 1995
Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patientsS Vandel, G Bertschy, P Baumann, et al.
L'Encephale|May 1, 1996
[Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration]B Bonin, G Bertschy, P Baumann, et al.
European Journal of Clinical Pharmacology|January 1, 1993
Minor and clinically non-significant interaction between toloxatone and amitriptylineS Vandel, G Bertschy, M C Perault, et al.
Neuropsychobiology|January 1, 1992
Tricyclic antidepressant plasma levels after fluoxetine additionS Vandel, G Bertschy, B Bonin, et al.
European Journal of Clinical Pharmacology|January 19, 2000
Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypesP Vandel, E Haffen, S Vandel, et al.
Clinical Neuropharmacology|January 1, 1992
Metabolic interaction between tricyclic antidepressant and fluvoxamine and fluoxetine, a pharmacogenetic approachG Bertschy, S Vandel, T Francois, et al.
Therapie|January 1, 1995
[Undesirable effects of drugs. Epidemiologic study at a psychiatric service of a university hospital]P Vandel, P Bizouard, S Vandel, et al.
European Journal of Clinical Pharmacology|May 11, 2000
Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?E Haffen, P Vandel, G Paintaud, et al.
Pageof 9